MyFinsight
Home
Blog
About
Cash and cash
equivalents
$72,054K
(72.63%↑ Y/Y)
Other current assets
$12,935K
(-9.90%↓ Y/Y)
R&d benefit
receivable
$9,292K
(-53.44%↓ Y/Y)
Total current assets
$94,281K
(-36.53%↓ Y/Y)
Goodwill
$10,325K
(-2.75%↓ Y/Y)
Property, plant and
equipment
$1,325K
(-25.35%↓ Y/Y)
Other intangible
assets
$237K
(-25.24%↓ Y/Y)
Other long-term
assets
$127K
(-96.75%↓ Y/Y)
Operating lease
right-of-use asset
$117K
(101.72%↑ Y/Y)
Total assets
$106,412K
(-35.60%↓ Y/Y)
Total liabilities and
shareholders' equity
$106,412K
(-35.60%↓ Y/Y)
Total liabilities
$67,941K
(-4.41%↓ Y/Y)
Total shareholders'
equity
$38,471K
(-59.14%↓ Y/Y)
Accumulated deficit
-$589,632K
(-11.28%↓ Y/Y)
Accumulated other
comprehensive loss
-$3,341K
(-137.96%↓ Y/Y)
Contract liabilities
$55,218K
(-1.94%↓ Y/Y)
Total current
liabilities
$12,714K
(-13.91%↓ Y/Y)
Operating lease
liabilities
$9K
Additional paid-in capital
$621,152K
(0.98%↑ Y/Y)
Ordinary shares - par
value gbp 0.05 per...
$10,292K
(0.02%↑ Y/Y)
Trade and other
payables
$12,611K
(-11.88%↓ Y/Y)
Operating lease
liabilities, current
$103K
Back
Back
Balance Sheet
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)
source: myfinsight.com